Study: NCT02738931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg tablet
Description: A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg tablet
Description: A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg tablet
Description: A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg tablet
Description: A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg tablet
Description: A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg tablet
Description: A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg tablet
Description: Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg tablet
Description: Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg tablet
Description: Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg tablet
Description: Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg tablet
Description: Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg tablet
Description: Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Description: Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.